Helix BioPharma Corp. has announced the voting results from its Annual General and Special Meeting of Shareholders held on January 30, 2026. A total of 61,885,815 common shares were voted, representing 81.03% of the company's total issued and outstanding shares, with shareholders voting overwhelmingly in favor of all items of business.
The four director nominees listed in the company's Management Information Circular dated December 15, 2025, were re-elected as directors with near-unanimous support. Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube each received 99.99% of votes in favor. Shareholders also approved the appointment of Clearhouse LLP as auditor with 99.99% support and authorized a share consolidation amendment with 99.99% approval.
The share consolidation amendment allows the board to consolidate issued and outstanding common shares at a ratio of up to five pre-consolidation shares for one post-consolidation share, with the final ratio to be determined at the board's discretion. A report on all meeting items will be filed on SEDAR+ at https://www.sedarplus.com.
For business and technology leaders monitoring the biopharmaceutical sector, these results indicate strong shareholder confidence in Helix's current leadership and strategic direction. The near-unanimous support for all measures suggests alignment between management and investors as the company advances its clinical-stage oncology pipeline.
Helix BioPharma is developing novel therapies for hard-to-treat cancers, with its pipeline spearheaded by a proprietary bio-conjugate technology platform targeting CEACAM6-expressing solid tumors. The company's lead candidate, L-DOS47, has completed Phase Ib studies in non-small cell lung cancer and represents a potential game-changing approach to cancer treatment by neutralizing tumor microenvironments and enhancing anti-cancer immunity.
The shareholder approval of the share consolidation measure provides the board with flexibility to potentially improve the company's capital structure and market perception. For investors and industry observers, this development comes as Helix continues to advance its clinical programs while managing the inherent risks of drug development detailed in its annual filings available at https://www.sedarplus.com.
As a clinical-stage company listed on multiple exchanges including TSX under symbol "HBP," Helix's governance decisions carry significant weight for stakeholders evaluating the company's trajectory in the competitive oncology therapeutics market. The overwhelming shareholder support for all agenda items suggests confidence in the company's ability to navigate the complex regulatory and development challenges ahead while advancing its mission to make hard-to-treat cancers vincible.
